Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options

Published:2020-04-26 Issue:5 Volume:20 Page:509-516
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Rosso Mattia¹²,Saxena Shrishti¹²,Chitnis Tanuja¹²³

Affiliation:

1. Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

2. Ann Romney Center for Neurologic Disease, Harvard Medical School, Boston, Massachusetts, USA

3. Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2020.1757434

Reference58 articles.

1. Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System

2. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

3. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

4. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease

5. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Between Serum Interleukin-32 Level and Disease Status in Cases with Neuromyelitis Optica Spectrum Disorders;Journal of Inflammation Research;2024-08

2. Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance;Neurology and Therapy;2024-07-16

3. Research progress on pathogenesis and clinical treatment of neuromyelitis optica spectrum disorders (NMOSDs);Clinical Neurology and Neurosurgery;2023-08

4. Benign COVID-19 in an Aggressive Case of Aquaporin-4 Neuromyelitis Optica Treated with Tocilizumab;Sclerosis;2022-10-12

5. IL-6 as a marker for NMOSD disease activity;Journal of Neuroimmunology;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3